Engineering TIL to Thrive in Hard-to-Treat Solid Tumors Using CRISPR/Cas9 Gene Editing
Time: 1:00 pm
day: Post-Conference Day - Tackling Solid Tumors
Details:
- Harnessing the advantages of polyclonal TIL products to elicit anti-tumor responses
- Rational design of engineered TIL, or eTIL, boosts anti-tumor potency and persistence
- eTIL may improve the overall patient experience with TIL therapy